Abstract
BackgroundControl of disease activity in patients with rheumatoid arthritis (RA) has become achievable using synthetic and biologic disease modifying anti-rheumatic drugs, both as monotherapy or in combination. However, residual inflammatory...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have